This abstract presents part of the recent discussion on the methods on how to estimate the maximum recommended starting dose (MRSD) for the first study in humans.
Purpose
This abstract presents part of the recent discussion on the methods on how to estimate the maximum recommended starting dose (MRSD) for the first study in humans.
Methods
In 2002, the US FDA published a draft guidance1) proposing an algorithm for deriving the MRSD. This draft guidance is based on the determination of a NOAEL in the most appropriate species, conversion of the NOAEL to a human equivalent dose (HED) based on the normalisation of doses to body surface area and the application of a safety factor (in general 10), i.e. MRSD=HED/10.
The NOAEL is defined as the highest dose level that does not produce a clinically or statistically significant increase in adverse effects. Usually , the scaling between species based on body surface, leads to a safer MRSD compared to scaling based on body weight. The principle applied in this guidance is based on the approach of allometric scaling (AS): Dose=aWb, whereby W is weight and a and b are scaling factors. This leads to the following equation for converting animal doses to HED: HED=animal NOAEL x (Wanimal/Whuman)(1-b).
Pharmacokinetically guided approaches Reigner et al.2) proposed the use of the lowest AUC at the NOAEL in various species as well as the predicted human clearance (CL): DOSehuman = AUC x predicted human clear- Limitations of the pharmacokinetically guided approach The FDA's position is, that in the majority of cases animal data are not available in sufficient detail to construct a scientifically valid, pharmacokinetic model to accurately project an MRSD.
In addition:
select the AUC for further calculations also applies for the PK-guided approach.
cantly from that in animals.
However, toxicity may be due to a (unknown) metabolite or a mechanism of toxicity not related to the PK of the parent drug.
an MRSD based on the NOAEL level in an appropriate species, AS to a HED plus application of a safety factor.
ture, which need PK data from various animal species to predict human clearance, again using AS, and thereafter estimating an MRSD. 
